Table 1.
Characteristics of 46,127 non-small cell lung cancer patients
| Variables | ICI with conventional therapies | Monotherapies | OTHER (N = 9792) | |||||
|---|---|---|---|---|---|---|---|---|
| ICI+CHEMO (N= 3110) | ICI+TARGET (N = 227) | ICI+RT (N = 483) | ICI (N = 15,263) | CHEMO (N = 6420) | TARGET (N = 10,796) | RT (N = 36) | ||
| Age | 65.6 (9.62) | 66.0 (11.5) | 68.3 (9.59) | 66.9 (10.1) | 64.0 (10.7) | 67.0 (12.0) | 58.9 (11.3) | 63.0 (11.9) |
| Sex | ||||||||
| Female | 931 (29.9) | 107 (47.1) | 117 (24.2) | 4569 (29.9) | 1856 (28.9) | 5837 (54.1) | 20 (55.6) | 4080 (41.7) |
| Male | 1954 (62.8) | 102 (44.9) | 337 (69.8) | 9527 (62.4) | 3153 (49.1) | 3744 (34.7) | 14 (38.9) | 4424 (45.2) |
| Not reported | 225 (7.2) | 18 (7.9) | 29 (6.0) | 1167 (7.6) | 1411 (22.0) | 1215 (11.3) | 2 (5.6) | 1288 (13.2) |
| Country | ||||||||
| Germany | 378 (12.2) | 5 (2.2) | 7 (1.4) | 684 (4.5) | 846 (13.2) | 303 (2.8) | 2 (5.6) | 479 (4.9) |
| France | 216 (6.9) | 14 (6.2) | 14 (2.9) | 1173 (7.7) | 616 (9.6) | 441 (4.1) | 0 (0) | 980 (10.0) |
| UK | 119 (3.8) | 3 (1.3) | 2 (0.4) | 278 (1.8) | 348 (5.4) | 1468 (13.6) | 1 (2.8) | 587 (6.0) |
| Japan | 896 (28.8) | 95 (41.9) | 392 (81.2) | 5384 (35.3) | 914 (14.2) | 2570 (23.8) | 3 (8.3) | 1854 (18.9) |
| USA | 641 (20.6) | 55 (24.2) | 22 (4.6) | 3651 (23.9) | 1636 (25.5) | 2413 (22.4) | 13 (36.1) | 2538 (25.9) |
| Others | 860 (27.7) | 55 (24.2) | 46 (9.5) | 4093 (26.8) | 2060 (32.1) | 3601 (33.4) | 17 (47.2) | 3354 (34.3) |
| Reporter occupation | ||||||||
| Healthcare professional | 1917 (61.6) | 161 (70.9) | 384 (79.5) | 10,342 (67.8) | 4730 (73.7) | 6573 (60.9) | 24 (66.7) | 7620 (77.8) |
| Non-healthcare professional | 1185 (38.1) | 60 (26.4) | 45 (9.3) | 4730 (31.0) | 1655 (25.8) | 3465 (32.1) | 12 (33.3) | 1999 (20.4) |
| Not reported | 8 (0.3) | 6 (2.6) | 54 (11.2) | 191 (1.3) | 35 (0.5) | 758 (7.0) | 0 (0) | 173 (1.8) |
| Year | ||||||||
| 2015 | 21 (0.7) | 3 (1.3) | 2 (0.4) | 576 (3.8) | 1113 (17.3) | 1446 (13.4) | 7 (19.4) | 1452 (14.8) |
| 2016 | 84 (2.7) | 26 (11.5) | 11 (2.3) | 1880 (12.3) | 837 (13.0) | 1735 (16.1) | 9 (25.0) | 1479 (15.1) |
| 2017 | 271 (8.7) | 45 (19.8) | 21 (4.3) | 2779 (18.2) | 1146 (17.9) | 2266 (21.0) | 6 (16.7) | 1419 (14.5) |
| 2018 | 609 (19.6) | 58 (25.6) | 68 (14.1) | 3952 (25.9) | 1527 (23.8) | 1898 (17.6) | 4 (11.1) | 2021 (20.6) |
| 2019 | 1275 (41.0) | 53 (23.3) | 251 (52.0) | 4163 (27.3) | 1223 (19.0) | 2370 (22.0) | 5 (13.9) | 2270 (23.2) |
| 2020 Q1–2 | 850 (27.3) | 42 (18.5) | 130 (26.9) | 1913 (12.5) | 574 (8.9) | 1081 (10.0) | 5 (13.9) | 1151 (11.8) |
| IP | ||||||||
| With IP | 290 (9.3) | 30 (13.2) | 446 (92.3) | 1579 (10.3) | 320 (5.0) | 591 (5.5) | 13 (36.1) | 561 (5.7) |
| Without IP | 2820 (90.7) | 197 (86.8) | 37 (7.7) | 13,684 (89.7) | 6100 (95.0) | 10,205 (94.5) | 23 (63.9) | 9231 (94.3) |
Classified variable data are shown as n (%)
IP Interstitial pneumonitis, RT Radiation therapy, CHEMO Chemotherapy, ICI Immune checkpoint inhibitor therapy, TARGET Targeted therapy, OTHER Other therapies not mentioned